ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,914.77
      0.13%
      US Tech 100
      20,681.40
      0.28%
      Dow Jones
      42,671.00
      0.23%
      Brent Oil
      74.565
      0.63%
      Bitcoin
      95,675.12
      3.25%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Caribou Biosciences Inc (CRBU) Quote

      Caribou Biosciences Inc

      Caribou Biosciences Inc (CRBU)

      Amd Commo Exagr
      1.555
      -0.055
      ( -3.42% )
      Updated: 10:25:32
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      1.555
      Bid
      1.55
      Ask
      1.56
      Volume
      412,053
      1.54 Day's Range 1.615
      1.50 52 Week Range 8.33
      Market Cap
      140.809M
      Previous Close
      1.61
      Open
      1.61
      Last Trade
      100
      @
      1.555
      Last Trade Time
      10:27:33
      Financial Volume
      $ 650,483
      VWAP
      1.5786
      Average Volume (3m)
      1,424,931
      Shares Outstanding
      90,552,687
      Dividend Yield
      -
      PE Ratio
      -1.41
      Earnings Per Share (EPS)
      -1.13
      Revenue
      34.48M
      Net Profit
      -102.07M

      About Caribou Biosciences Inc

      Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies.

      Sector
      Biological Pds,ex Diagnstics
      Industry
      Biological Pds,ex Diagnstics
      Website
      www.cariboubio.com
      Headquarters
      Dover, Delaware, USA
      Founded
      -
      Caribou Biosciences Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker CRBU. The last closing price for Caribou Biosciences was $1.61. Over the last year, Caribou Biosciences shares have traded in a share price range of $ 1.50 to $ 8.33.

      Caribou Biosciences currently has 90,552,687 shares outstanding. The market capitalization of Caribou Biosciences is $145.79 million. Caribou Biosciences has a price to earnings ratio (PE ratio) of -1.41.

      Ask ADVFN Intelligence (AI)

      CRBU Latest News

      More News

      Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

      December 06 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      November 22 2024
      Edgar (US Regulatory)

      Caribou Biosciences to Participate in Upcoming Investor Conferences

      BERKELEY, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel...

      November 20 2024
      GlobeNewswire Inc.

      Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

      November 14 2024
      Edgar (US Regulatory)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      November 06 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      November 06 2024
      Edgar (US Regulatory)

      Caribou Biosciences Reports Third Quarter 2024 Financial Results and  Provides Business Update

      -- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; multiple clinical data reports planned for 2025 -- -- Enrolling patients with LBCL (2L and after...

      November 06 2024
      GlobeNewswire Inc.

      Form 3 - Initial statement of beneficial ownership of securities

      October 04 2024
      Edgar (US Regulatory)

      Form 8-K/A - Current report: [Amend]

      September 27 2024
      Edgar (US Regulatory)

      Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024

      BERKELEY, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced an...

      September 25 2024
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.245-13.61111111111.81.8051.5414149831.66192036CS
      4-0.795-33.8297872342.352.361.5413715191.89205329CS
      12-0.265-14.56043956041.822.99951.5414249312.10675208CS
      26-0.105-6.325301204821.662.99951.513553472.10482318CS
      52-4.155-72.76707530655.718.331.516734133.31393261CS
      156-13.435-89.626417611714.9915.851.513115475.27926811CS
      260-16.095-91.189801699717.6532.6451.512275836.45555201CS

      CRBU - Frequently Asked Questions (FAQ)

      What is the current Caribou Biosciences share price?
      The current share price of Caribou Biosciences is $ 1.555
      How many Caribou Biosciences shares are in issue?
      Caribou Biosciences has 90,552,687 shares in issue
      What is the market cap of Caribou Biosciences?
      The market capitalisation of Caribou Biosciences is USD 145.79M
      What is the 1 year trading range for Caribou Biosciences share price?
      Caribou Biosciences has traded in the range of $ 1.50 to $ 8.33 during the past year
      What is the PE ratio of Caribou Biosciences?
      The price to earnings ratio of Caribou Biosciences is -1.41
      What is the cash to sales ratio of Caribou Biosciences?
      The cash to sales ratio of Caribou Biosciences is 4.18
      What is the reporting currency for Caribou Biosciences?
      Caribou Biosciences reports financial results in USD
      What is the latest annual turnover for Caribou Biosciences?
      The latest annual turnover of Caribou Biosciences is USD 34.48M
      What is the latest annual profit for Caribou Biosciences?
      The latest annual profit of Caribou Biosciences is USD -102.07M
      What is the registered address of Caribou Biosciences?
      The registered address for Caribou Biosciences is 3500 S DUPONT HWY, KENT, DOVER, DELAWARE, 19901
      What is the Caribou Biosciences website address?
      The website address for Caribou Biosciences is www.cariboubio.com
      Which industry sector does Caribou Biosciences operate in?
      Caribou Biosciences operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      APMAptorum Group Ltd
      $ 5.142
      (279.48%)
      		59.15M
      ONCOOnconetix Inc
      $ 1.60
      (266.13%)
      		143.87M
      VRMEVerifyMe Inc
      $ 2.10
      (165.86%)
      		73.14M
      BDMDBaird Medical Investment Holdings Ltd
      $ 2.6863
      (155.84%)
      		5.21M
      FLYEFly E Group Inc
      $ 1.2691
      (89.42%)
      		40.16M
      SGMOSangamo Therapeutics Inc
      $ 1.1306
      (-51.68%)
      		14.02M
      WATTEnergous Corporation
      $ 1.5201
      (-42.64%)
      		14.66M
      COCPCocrystal Pharma Inc
      $ 2.03
      (-37.54%)
      		239.3k
      HUBCWHub Cyber Security Ltd
      $ 0.035
      (-36.36%)
      		218.55k
      ARTWArts Way Manufacturing Co Inc
      $ 2.4153
      (-32.91%)
      		661.92k
      SVMHSRIVARU Holding Ltd
      $ 0.059
      (76.65%)
      		407.31M
      EYENEyenovia Inc
      $ 0.1431
      (26.30%)
      		261.08M
      CRKNCrown Electrokinetics Corporation
      $ 0.179
      (29.06%)
      		232.79M
      XTIAXTI Aerospace Inc
      $ 0.0429
      (8.61%)
      		206.21M
      ONCOOnconetix Inc
      $ 1.60
      (266.13%)
      		143.87M

      CRBU Discussion

      View Posts
      Monksdream Monksdream 1 week ago
      CRBU under $2
      👍️0
      TrendTrade2016 TrendTrade2016 2 months ago
      CRBU READY TO BEAST
      👍️0
      TrendTrade2016 TrendTrade2016 2 months ago
      CRBU...NEW SCAN JUST GAVE ME THIS BIO
      👍️0
      Monksdream Monksdream 2 months ago
      CRBU under $3
      👍️0
      Monksdream Monksdream 3 months ago
      CRBU under $2
      👍️0
      Monksdream Monksdream 4 months ago
      CRBU under $3
      👍️0
      Monksdream Monksdream 5 months ago
      CRBU under $3
      👍️0
      jondoeuk jondoeuk 5 months ago
      Earlier this year development of the lead CAR-NK programme, CB-020, was stopped, and now they are out of CAR-NK altogether. They disclosed it in an SEC filing and outlined a 12% workforce reduction https://www.sec.gov/Archives/edgar/data/1619856/000161985624000054/crbu-20240716.htm

      This should extend their cash runway by at least six months, into the second half of 2026.
      👍️0
      Monksdream Monksdream 5 months ago
      CRBU under $3
      👍️0
      Monksdream Monksdream 6 months ago
      CRBU new 52 week low
      👍️0
      Monksdream Monksdream 6 months ago
      CRBU new 52 week low
      👍️0
      NY1972 NY1972 7 months ago
      Without engaging macrophage long term, CART and other ACT will have persistence issue as regulatory lymphocytes and TAM recoup. AFMD has the best approach with ICE engaging a few B CBNK cells for start and engaging endogenous NK and M in the maintenance phase
      👍️0
      Diego Rivas Diego Rivas 7 months ago
      Any good news in here comming?
      👍️0
      jondoeuk jondoeuk 7 months ago
      Among patients with four or more matching HLA alleles, mPFS was 14.4 months, versus 2.8 months in patients with three or fewer matches. But this is based on a retrospective analysis, so they will need to prove the theory prospectively. It was better in LBCL, with mPFS not reached, versus 2.8 months. Also, some improvement in the now-selected dose, 80 million CAR-T cells.
      👍️0
      jondoeuk jondoeuk 7 months ago
      The BCMA-targeted space is already crowded enough and off-target toxicities, including agranulocytosis* could be a problem for its anti-CLL-1 CAR.

      * CLL-1 is also highly expressed on almost all granulocytes and monocytes and on parts of myeloid progenitors in the normal bone marrow and peripheral blood.
      👍️0
      Monksdream Monksdream 7 months ago
      CRBU new 52 week low
      👍️0
      stocksrising stocksrising 7 months ago
      Yep, not a positive trend hence sub $3’s…fortunately other trials for varied indications could save company…
      👍️0
      jondoeuk jondoeuk 7 months ago
      It gets worse. The updated (CB-010) data shows that the ORR (including CR rate) has fallen, so has the mDOR, the six-month PFS is poor and the pivotal trial has been delayed until H2 2025 following a new HLA partial matching strategy. The latter completely alters (in a bad way) the commercial strategy for an allo CAR-T product. They now need thirteen different off-the-shelf batches to be able to cater to ~90% of patients based on an ideal HLA match.
      👍️ 1
      Monksdream Monksdream 7 months ago
      CRBU new 52 week low
      👍️0
      Monksdream Monksdream 7 months ago
      CRBU new 52 week low
      👍️0
      Monksdream Monksdream 8 months ago
      CRBU under $5
      👍️0
      stocksrising stocksrising 10 months ago
      It seemed like they were running on all positive cylinders, but must have blown a gasket at current Conference/ Fireside???
      👍️0
      Monksdream Monksdream 1 year ago
      CRBU new 52 week low
      👍️0
      jondoeuk jondoeuk 1 year ago
      Yes, with both drugs still in development. As for CRBU, they gave an update (plus public offering) https://finance.yahoo.com/news/caribou-biosciences-reports-positive-clinical-200100822.html https://investor.cariboubio.com/static-files/d818ed1a-aea2-41c1-84ea-bd05a4276cbb

      Personally, there seem to be red flags, such as no expansion/persistence data. I know they give huge amounts of LD chemo, higher (I think) than anyone else, which could be generating responses, explaining why there is no dose response.
      👍️0
      trueblue trueblue 1 year ago
      .
      👍️0
      trueblue trueblue 1 year ago
      $23.00 price target! Now that is a good start!! Glad I loaded up! Jmo
      👍️0
      NY1972 NY1972 1 year ago
      Didn't they buy TRIL? Just gambling with billions from US government.
      👍️0
      jondoeuk jondoeuk 1 year ago
      PFE is very selective in who they fund https://finance.yahoo.com/news/caribou-biosciences-announces-25-million-120000433.html
      👍️0
      trueblue trueblue 1 year ago
      Great day in my accounts again! Really liking my CRBU shares! Jmo holding for the long haul!!
      👍️0
      Monksdream Monksdream 1 year ago
      CRBU now No 9 on the Barchart Top 10
      https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
      👍️0
      trueblue trueblue 1 year ago
      Added to my existing shares today, I bought shares months ago. I like Crbu a crisper company! Looks like Pfizer does also! Jmo
      👍️0
      Stockexpertpro Stockexpertpro 1 year ago
      CRBU Loss 108 Million Dollars Company only has preclinical and phase 1 in its pipeline company is Years away from having anything if ever did a stock offering at 5.33$ for 25 Million thats only 1 QTR Cash burn for this company Sell the News https://www.cariboubio.com/pipeline/
      👍️0
      TheFinalCD TheFinalCD 1 year ago
      CRBU= JUST WOW

      https://finviz.com/quote.ashx?t=CRBU&ty=c&ta=1&p=d
      👍️0
      Monksdream Monksdream 1 year ago
      CRBU No 1 on the early Barchart Top 100
      https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
      👍️0

      Your Recent History

      NASDAQ
      CRBU
      Caribou Biosciences
      BIT
      P13ZD7
      BNP Paribas Issuance
      BIT
      P1JNC1
      BNP Paribas Issuance BV
      TG
      A3L3WA
      Republic Of Romania
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads